208370.KQ Hana Must SPAC 2
- Market cap
- KRW 54.3B
- P/E
- 6.4x
- P/B
- 0.72x
- ROE
- 12.0%
- Dividend yield
- -
- Fundamental score
- 2.7/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 208370.KQ undervalued?
Graham number208370.KQ trades 54.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hana Must SPAC 2 fundamental analysis
14 of 22 checks passedROE 1/2
Moderate return on equity (12.0%), between 10% and 20%.
ROA 1/1
Return on assets (10.7%) is above the industry median (6.2%).
Profit Consistency 2/2
Profitable for 6 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (23.4%) is not above the 5-year average (34.0% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (23.4%) is above the industry median (0.5%).
Revenue Growth 1/2
Revenue grew 3.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
EBIT is 123.2x against interest expense, well covered.
PE vs Market 1/1
PE (6.4x) is below the market median (11.3x).
PE vs Industry 1/1
PE (6.4x) is below the industry median (7.6x).
PBV 1/1
Price to book (0.7x) is below the industry median (0.7x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 4.6, limit 22.5).
PEG 1/1
PEG on 5-year earnings growth is 0.19, growth is cheap.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Hana Must SPAC 2 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hana Must SPAC 2
SELVAS Healthcare, Inc. operates as a medical device company in South Korea. The company provides body composition analyzers and automatic blood pressure monitors for hospitals. It also offers Braille Sense notetakers and other products for blind and visually impaired people under the HIMS brand name, as well as provides digital health products under the ACCUNIQ brand name. In addition, The company provides daisy players, handheld, and desktop magnifiers. Its products are us…
Full company profileHana Must SPAC 2 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hana Must SPAC 2 annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 23.1B | 29.6B | 20.0B | 22.4B | 21.2B | 29.1B | 27.7B | 29.8B | 31.7B | 30.8B | 29.6B |
| Gross Profit | 9.17B | 12.9B | 3.73B | 8.46B | 9.76B | 14.0B | 14.1B | 15.7B | 16.6B | 15.0B | 14.8B |
| Operating Income | -8.35B | 149M | -19.0B | -3.45B | 858M | 3.30B | 1.94B | 3.35B | 3.27B | -162M | 2.08B |
| EBITDA | - | - | - | - | - | - | 4.46B | 5.10B | 4.58B | 5.88B | 10.2B |
| Net Income | -14.9B | -1.12B | -20.0B | -3.33B | 759M | 2.47B | 2.81B | 5.17B | 3.15B | 3.89B | 9.09B |
| EPS | -1,178 | -85 | -1,523 | -154 | 35 | 110 | 126 | 201 | 123 | 151 | 354 |
| Balance Sheet | |||||||||||
| Total Assets | 45.5B | 54.7B | 41.3B | 47.1B | 45.1B | 49.0B | 45.1B | 66.7B | 70.2B | 79.0B | 85.2B |
| Total Liabilities | 18.6B | 26.9B | 26.7B | 23.0B | 20.2B | 20.9B | 12.2B | 6.58B | 6.42B | 7.86B | 9.41B |
| Shareholders' Equity | 26.9B | 27.8B | 14.6B | 24.1B | 24.9B | 28.1B | 32.9B | 60.1B | 63.8B | 71.1B | 75.8B |
| Cash & Short-term Investments | 4.71B | 3.29B | 1.43B | 12.9B | 13.6B | 14.9B | 7.06B | 24.3B | 26.1B | 9.38B | 2.95B |
| Total Debt | - | - | 10.6B | 8.43B | 6.95B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.23B | -4.30B | -6.90B | 3.69B | 4.23B | 2.93B | 50.8M | 3.47B | 4.50B | 305M | 1.53B |
| Capital Expenditure | 5.09B | 8.25B | 677M | 133M | 138M | 376M | 361M | 369M | 737M | 1.10B | 2.17B |
| Free Cash Flow | - | - | - | 4.45B | 4.09B | 2.55B | -310M | 3.10B | 3.76B | -797M | -639M |
| Ratios | |||||||||||
| ROE | -55.2% | -4.0% | -136.9% | -13.8% | 3.0% | 8.8% | 8.6% | 8.6% | 4.9% | 5.5% | 12.0% |
| ROA | -32.7% | -2.0% | -48.5% | -7.1% | 1.7% | 5.0% | 6.2% | 7.8% | 4.5% | 4.9% | 10.7% |
| Net Profit Margin | -64.4% | -3.8% | -99.8% | -14.9% | 3.6% | 8.5% | 10.2% | 17.3% | 9.9% | 12.6% | 30.7% |
| Debt to Equity | - | - | 0.72x | 0.35x | 0.28x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hana Must SPAC 2 dividends
Hana Must SPAC 2 has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Jan 16, 2017.
Who owns Hana Must SPAC 2
- Insiders 39.66%
- Institutions 0.03%
- Public & others 60.31%
- Shares outstanding 25.7M
- Free float 15.5M
Hana Must SPAC 2 company profile
- Company name
- Hana Must SPAC 2
- Ticker
- 208370.KQ
- ISIN
- KR7208370007
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 129
- Fiscal year end
- December
- Address
- 155, Sinseong-ro, Daejeon, South Korea, 34109
- Phone
- 82 4 2879 3000
- Website
- selvashealthcare.com
About Hana Must SPAC 2
SELVAS Healthcare, Inc. operates as a medical device company in South Korea. The company provides body composition analyzers and automatic blood pressure monitors for hospitals. It also offers Braille Sense notetakers and other products for blind and visually impaired people under the HIMS brand name, as well as provides digital health products under the ACCUNIQ brand name. In addition, The company provides daisy players, handheld, and desktop magnifiers. Its products are used in hospitals, medical facilities, doctor's offices, weight loss centers, Fitness Centers, nursing homes, public health facilities, and retail locations. The company was formerly known as Jawon Medical Co., Ltd. and changed its name to SELVAS Healthcare, Inc. in September 2016. SELVAS Healthcare, Inc. was founded in 1993 and is headquartered in Daejeon, South Korea.
Hana Must SPAC 2 management
5- Mr. Chul-Joong KwonCEO & Director · born 1965
- Mr. Byung-Tak YooCEO & Director · born 1974
- Mr. Woo-Jae LeeMD & Chief of Marketing Office · born 1969
- Mr. Haeseok LeeExecutive Director · born 1980
- Mr. Min-Cheol KwakExecutive Director · born 1975